| Novo |
00169430313 |
Rybelsus Oral Tablet 3mg |
2019-10-22 |
772.4300 |
None |
1 |
1400000 |
None |
1 |
None |
None |
None |
None |
RYBELSUS® is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The estimated patients figure is based on the total estimated number of patients in the United States who utilize GLP-1 RA therapies and therefore are likely candidates for RYBELSUS®. It is not an estimate of prescriptions that might be written for each available dose of RYBELSUS®. RYBELSUS® will represent a portion of the broader market for GLP-1 RA therapies. |
None |
| Novo |
00169430713 |
Rybelsus Oral Tablet 7mg |
2019-10-22 |
772.4300 |
None |
1 |
1400000 |
None |
1 |
None |
None |
None |
None |
RYBELSUS® is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The estimated patients figure is based on the total estimated number of patients in the United States who utilize GLP-1 RA therapies and therefore are likely candidates for RYBELSUS®. It is not an estimate of prescriptions that might be written for each available dose of RYBELSUS®. RYBELSUS® will represent a portion of the broader market for GLP-1 RA therapies. |
None |
| Novo |
00169431413 |
Rybelsus Oral Tablet 14mg |
2019-10-22 |
772.4300 |
None |
1 |
1400000 |
None |
1 |
None |
None |
None |
None |
RYBELSUS® is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The estimated patients figure is based on the total estimated number of patients in the United States who utilize GLP-1 RA therapies and therefore are likely candidates for RYBELSUS®. It is not an estimate of prescriptions that might be written for each available dose of RYBELSUS®. RYBELSUS® will represent a portion of the broader market for GLP-1 RA therapies. |
None |
| Novartis |
00078098615 |
MAYZENTTM is available as 2 mg tablet (equivalent to 2.224mg siponimod fumaric acid): pale yellow, unscored, round biconvex film-coated tablet with beveled edges, debossed with Novartis symbol on one side and “T” on other side. |
2019-03-27 |
7273.9700 |
Novartis considered many factors in determining the price of Mayzent. As the first oral drug to delay disability progression in RRMS, CIS, and active SPMS, Mayzent is poised to substantially reduce the burden of the condition on patients, caregivers, employers, insurers, the US healthcare system and society as a whole. We are focused on access to Mayzent for this patient population. |
None |
320000 |
None |
1 |
None |
None |
None |
None |
Novartis used a priority review voucher. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
None |
| Novartis |
00078097950 |
MAYZENTTM is available as 0.25 mg tablet (equivalent to 0.278mg siponimod fumaric acid): Pale red, unscored, round biconvex film-coated tablet with beveled edges, debossed with Novartis symbol on one side and “T” on other side. |
2019-03-27 |
1697.2600 |
Novartis considered many factors in determining the price of Mayzent. As the first oral drug to delay disability progression in RRMS, CIS, and active SPMS, Mayzent is poised to substantially reduce the burden of the condition on patients, caregivers, employers, insurers, the US healthcare system and society as a whole. We are focused on access to Mayzent for this patient population. |
None |
320000 |
None |
1 |
None |
None |
None |
None |
Novartis used a priority review voucher. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
None |
| Novartis |
00078070802 |
Piqray 300 mg /56 tablets (150mg tabs) |
2019-05-24 |
15500.0000 |
Novartis considered many factors in determining the price of Piqray. We consider the value the medicine brings to the patient population, the healthcare system, and society. We also consider the research and development costs, as well as ongoing costs for marketing, regulatory commitments, ongoing pharmacovigilance, and market conditions and dynamics. Piqray is the first and only treatment specifically for the approximately 40% of HR+/HER2- advanced breast cancer patients with a PIK3CA mutation, bringing a biomarker-driven therapy option to people with HR+/HER2- advanced breast cancer for the first time. Advanced breast cancer is incurable, and patients with all types need more treatment options. With this approval, physicians can now use an FDA-approved test to determine if their patients’ HR+/HER2- advanced breast cancer has a PIK3CA mutation and may benefit from Piqray combination therapy. We are focused on access to Piqray for this patient population. |
None |
43000 |
None |
None |
None |
None |
None |
None |
Novartis developed Piqray. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
None |
| Novartis |
00078071502 |
Piqray 250 mg / 56 tablets (28 of the 200 mg tabs & 28 of the 50 mg tabs) |
2019-05-24 |
15500.0000 |
Novartis considered many factors in determining the price of Piqray. We consider the value the medicine brings to the patient population, the healthcare system, and society. We also consider the research and development costs, as well as ongoing costs for marketing, regulatory commitments, ongoing pharmacovigilance, and market conditions and dynamics. Piqray is the first and only treatment specifically for the approximately 40% of HR+/HER2- advanced breast cancer patients with a PIK3CA mutation, bringing a biomarker-driven therapy option to people with HR+/HER2- advanced breast cancer for the first time. Advanced breast cancer is incurable, and patients with all types need more treatment options. With this approval, physicians can now use an FDA-approved test to determine if their patients’ HR+/HER2- advanced breast cancer has a PIK3CA mutation and may benefit from Piqray combination therapy. We are focused on access to Piqray for this patient population. |
None |
43000 |
None |
None |
None |
None |
None |
None |
Novartis developed Piqray. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
None |
| Novartis |
00078070184 |
Piqray 200 mg / 28 tablets (28 of the 200mg tabs) |
2019-05-24 |
15500.0000 |
Novartis considered many factors in determining the price of Piqray. We consider the value the medicine brings to the patient population, the healthcare system, and society. We also consider the research and development costs, as well as ongoing costs for marketing, regulatory commitments, ongoing pharmacovigilance, and market conditions and dynamics. Piqray is the first and only treatment specifically for the approximately 40% of HR+/HER2- advanced breast cancer patients with a PIK3CA mutation, bringing a biomarker-driven therapy option to people with HR+/HER2- advanced breast cancer for the first time. Advanced breast cancer is incurable, and patients with all types need more treatment options. With this approval, physicians can now use an FDA-approved test to determine if their patients’ HR+/HER2- advanced breast cancer has a PIK3CA mutation and may benefit from Piqray combination therapy. We are focused on access to Piqray for this patient population. |
None |
43000 |
None |
None |
None |
None |
None |
None |
Novartis developed Piqray. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
None |
| Novartis |
00078082761 |
BEOVU® (brolucizumab-dbll) |
2019-10-08 |
1850.0000 |
Novartis considered many factors in determining the price of Beovu®. We believe Beovu is poised to substantially reduce the burden of Neovascular (Wet) Age-Related Macular Degeneration (AMD) on patients, caregivers, insurers, the US healthcare system and society as a whole. With our pricing methodology, we are focused on access to BEOVU® for this patient population. |
None |
700000 |
None |
1 |
None |
None |
None |
None |
There are 700,000 patients with wAMD in the US for whom Beovu® may be prescribed; however, it is most likely only 53,000 US patients may potentially be prescribed Beovu® in 2020. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
None |
| Novartis |
00078088361 |
ADAKVEO® (crizanlizumab-tmca) injection is a sterile, clear to opalescent, colorless to slightly brownish-yellow solution for intravenous infusion supplied as: |
2019-11-18 |
2357.1400 |
Novartis considered many factors in determining the price of Adakveo® including the value the medicine brings to the patient population, the healthcare system, and society. Adakveo® is the first targeted therapy to prevent the painful vaso-occlusive crises (VOCs) that patients with sickle cell disease endure. We believe Adakveo® is posed to reduce the burden of VOCs on patients with sickle cell disease, caregivers, the US healthcare system and society as a whole. We are focused on access to Adakveo® for this patient population. For marketing, we anticipate multi-channel advertising & promotion for Adakveo®. |
None |
2048 |
1 |
1 |
2016-11-18 |
665000000.0000 |
None |
Reprixys Pharmaceuticals Corporation, formerly known as Selexys Pharmaceutical Corporation, was acquired by Novartis for $665M. This product was a part of the portfolio acquired by Novartis. |
Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
None |